

6TH ICHNO

International Conference
on innovative approaches in

HEAD & NECK ONCOLOGY

16-18 March 2017
Barcelona, Spain

PROGRAMME BOOK
AND EXHIBITION GUIDE





ESTRO 36

5 - 9 May 2017
Vienna, Austria



Do not miss the opportunity to access cutting-edge data showcased by world class oncology experts, and to apply the take-home knowledge to your current practice

#ESTRO36

WWW.ESTRO.ORG



ESTRO
European Society for
RADIOTHERAPY
& ONCOLOGY



6TH ICHNO

International Conference on innovative
approaches in Head & Neck Oncology

16-18 March 2017
Barcelona, Spain

TABLE OF CONTENTS

GENERAL INFORMATION	3
Introduction 4	
Scientific and organising committees 6	
Acknowledgement 7	
Accreditation 8	
General information 9	
Programme overview 11	
SCIENTIFIC PROGRAMME	13
Thursday 16 March 2017 14	
Friday 17 March 2017 18	
Saturday 18 March 2017 23	
POSTERS	27
EXHIBITION	41
Floorplan 42	
Company details 43	
Acknowledgement to the industry 45	
SATELLITE SYMPOSIA	47
Thursday 16 March 2017 48	
Friday 17 March 2017 50	
AUTHORS INDEX	51



GENERAL INFORMATION

INTRODUCTION

A LETTER OF WELCOME FROM THE CONFERENCE CHAIRPERSONS

The 6th International Conference on innovative approaches in Head and Neck Oncology (ICHNO) will be held from 16 to 18 March 2017 in Barcelona, Spain.

The European Society for Radiotherapy and Oncology (ESTRO), the European Head and Neck Society (EHNS) and the European Society of Medical Oncology (ESMO) have the pleasure to welcome you at this conference.

This biennial conference will once again provide a unique platform for the dissemination of the most relevant and cutting edge science and innovation in the field of head and neck oncology. This conference has been shaping up to be a major international event in promoting multidisciplinary in head and neck oncology.

With major emphasis on head and neck, this meeting will specifically cover the main following topics:

- New insights in the epidemiology and prevention of cancer
- Oncogenesis, HPV related cancers, immunology and vaccination
- Updated results of practice changing randomised trials
- Multidisciplinary management of cancers
- Molecular targeted therapies and molecular imaging
- Novel radiation and surgical treatments
- Towards individualised management of cancer
- Robotic and minimally invasive surgery
- Reconstructive and salvage surgery
- Elderly patients, co-morbidities and their impact on management
- New insight in systemic treatments of cancers
- Thyroid, nasopharynx cancers and rare cancers
- Quality of life, supportive care and management of treatment side effects.

The format of the meeting includes prestigious invited 'state of the art lectures'; lectures on the latest innovative approaches; proffered papers and poster presentations of new data in the field of head and neck oncology. The programme is enriched by a debate and interactive tumour board session where the audience will have the possibility to participate and share their input via an electronic voting system. There is also a special focus on presentations of new data from practice changing randomised trials. Ample time will be given for discussions to allow in-depth interaction among the various disciplines and the participants.

To stimulate multidisciplinary interactions among the various specialists, all the lectures, debates, tumour boards and proffered papers are given in the same conference room.

We hope that the mix of a rich and challenging scientific programme coupled with the enticing atmosphere of the city of Barcelona will make your attendance worthwhile.

Chairpersons of the 6th ICHNO conference



Hans Langendijk
ESTRO



C. René Leemans
EHNS



Jean-Pascal Machiels
ESMO

SCIENTIFIC AND ORGANISING COMMITTEES

SCIENTIFIC COMMITTEE

H. Langendijk (NL), Chair
C.R. Leemans (NL), Chair
J.P. Machiels (BE), Chair
R. Brakenhoff (NL)
S. Faivre (FR)
K. Harrington (UK)
P. Nicolai (IT)

ADVISORY COMMITTEE FOR RADIATION ONCOLOGY

K. Harrington (UK), Chair
P. Blanchard (FR)
V. Budach (DE)
J. Giralt (ES)
C. Grau (DK)
V. Grégoire (BE)
D. Raben (US)
S. Tribius (DE)

ADVISORY COMMITTEE FOR MEDICAL ONCOLOGY

S. Faivre (FR), Chair
E. Cohen (US)
U. Keilholz (DE)
C. Le Tourneau (FR)
L. Licitra (IT)
P. Szturz (CZ)
M. Tahara (JP)
J. Vermorken (BE)

ADVISORY COMMITTEE FOR SURGERY

P. Nicolai (IT), Chair
R. de Bree (NL)
W. Golusinski (PL)
J. Klozar (CZ)
J.P. Klussmann (DE)
A. Mäkitie (JP)
R. Simo (UK)
S. Stoeckli (CH)
V. Vander Poorten (BE)

ADVISORY COMMITTEE FOR HEAD AND NECK CANCER RELATED SCIENCES

R. Brakenhoff (NL), Chair
J.F. Bakema (NL)
J. Hess (DE)
K. Hunter (UK)
H. Mehanna (UK)
M. Robinson (UK)
J.P. Machiels (BE)
N. Stoecklein (DE)

ACKNOWLEDGEMENT

ESTRO, the European Society for Radiotherapy and Oncology,
EHNS, the European Head and Neck Society,
And ESMO, the European Society for Medical Oncology,

Wish to thank the Scientific Committee Chairs, Hans Langendijk, C. René Leemans and Jean-Pascal Machiels for having accepted the responsibility to develop the scientific programme of this conference. A special thank you to the members of the advisory committees for having supported the development of the programme.

ACCREDITATION

The 6th ICHNO conference is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 6th ICHNO conference is designated for a maximum of (or 'for up to') 15 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

6th ICHNO Conference is accredited with 16 Category 1 ESMO MORA Points.

GENERAL INFORMATION

VENUE

Fira Barcelona
Avda. Reina Maria Cristina
08004 Barcelona
Spain

ACCOMMODATION

The official housing agent for the conference will be Kuoni Congress and they will operate an accommodation desk in the registration area on:
Thursday 16 March: 09:00 – 16:30
Friday 17 March: 09:00 – 16:30
Saturday 18 March: 09:00 – 13:00

CERTIFICATES

Certificates of attendance will be issued as of Friday 17 March in the afternoon through the designated stations in the registration area.

CURRENCY

The currency in Spain is the EURO.

OFFICIAL LANGUAGE

The official language of the meeting is English. No simultaneous translation will be provided.

POSTERS

The poster area will be in the exhibition hall and therefore, posters may be viewed at any time during conference hours.

EXHIBITION

An exhibition featuring radiotherapy equipment and pharmaceutical companies as well as medical publishers will be held in the exhibition area.

The exhibition will be open during the following times:
Thursday 16 March as from 09:30 to 20:00
Friday 17 March from 09:30 to 17:00
Saturday 18 March from 09:30 to 11:00.

Entrance is free for all the registered participants.

INSURANCE

The organiser does not accept liability for individual medical, travel or personal insurance. Participants are strongly advised to take out their own personal insurance policies.

In case an unforeseen event would force ESTRO to cancel the meeting, the Society will reimburse the participants the registration fee minus 15% for handling charges. ESTRO will not be responsible for the refund of travel and accommodation costs.

LUNCHEONS AND REFRESHMENTS

The registration fee for the conference includes lunches and coffee breaks served in the exhibition area.

NETWORKING EVENING

All participants and company delegates are invited to the networking evening on Thursday 16 March 2017 from 19:00 to 20:00. The networking evening will take place in the exhibition area.

WIFI

Wifi will be available in the whole congress centre

TRAVEL INFORMATION

How to reach Barcelona from the airport:

TAXI

El Prat International Airport is approximately 14 kilometres south-west of the centre of Barcelona and taxis are available at the airport 24 hours a day. It takes roughly between twenty and forty minutes into the centre of town and the fare is about € 30-45; tariffs can vary according to the time of day and supplements (eg luggage). The fares should be displayed in the taxi and the amount payable should be indicated on the meter.

AEROBUS

AEROBÚS is the official shuttle bus service that connects the airport BCN-El Prat and the centre of Barcelona every 5 minutes, every day of the year, in approximately 35 minutes. This is the fastest way to reach the city centre with public transport.

Passengers are able to travel between any of the two airport terminals (T1 or T2) and the centre of Barcelona (Pl. Catalunya) in only three stops in a fast, comfortable and economical way.

Along the route there are stops at the most important points of the city: Pl. Catalunya, Sepúlveda-Urgell, Pl. Espanya, Gran Via-Urgell, and Pl. Universitat.

Buses are adapted for persons with reduced mobility (PRM).

They dispose over a wide space especially designed for your luggage.
Free wifi and USB chargers on board.
Price single ticket: € 5,9.

METRO

The subway (or metro) now connects both terminals of the Airport with Barcelona underground network.

The line is called L9 Sud. There are stops at T1 (inside the building) and T2 (outside the building, next to train station), in both cases follow the signs.

The L9 Sud runs directly from Barcelona Airport to the South Entrance at Fira Gran Via.

TRAIN

You can catch the train from Clot, Passeig de Gracia, or Barcelona Sants (Sants Estacio). The name of the stop you want for the airport is Aeroport.

If travelling from the airport to the city centre you can get off at Barcelona Sants, Passeig de Gracia or Clot which are serviced by metro stops. From these you can change for the Barcelona metro underground system to go to your final destination.

PROGRAMME OVERVIEW

Thursday 16 March 2017

09:00-09:15	Opening remarks
09:15-09:45	Keynote lecture 1: Immunotherapy for head and neck cancer: integrating the fourth modality
09:45-10:15	Keynote lecture 2: State of the art in robotic surgery
10:15-10:45	Coffee break
10:45-12:00	Symposium 1: Prognostic modelling
12:00-13:00	Proffered papers 1
13:00-14:30	Lunch and Satellite symposium
14:30-16:00	New data from randomised trials
16:00-16:30	Coffee break
16:30-17:45	Symposium 2: Reductions of radiation induced toxicities
17:55-18:55	Satellite symposium
19:00-20:00	Networking evening

Friday 17 March 2017


09:00-09:30	Keynote lecture 3: New imaging techniques
09:30-10:00	Keynote lecture 4: HNC biomarkers - how do we translate biology into useful assays for clinical care?
10:00-10:30	Coffee break
10:30-11:30	Proffered papers 2
11:30-12:45	Symposium 3: New developments in surgery
12:45-14:15	Lunch and Satellite symposium
14:15-15:15	Interactive tumour board session: Limited T4a larynx cancer
15:15-16:00	Poster discussion
16:00-16:30	Coffee break
16:30-17:45	Symposium 4: New developments in systemic treatment

Saturday 18 March 2017

08:45-09:15	Keynote lecture 5: Clinical implementation of adaptive radiotherapy: challenges ahead
09:15-10:30	Symposium 5: Adenoid cystic carcinoma
10:30-11:00	Coffee break
11:00-12:00	Proffered papers 3
12:00-13:00	Debate 1: Early stage HPV related oropharyngeal cancer should not be treated with radiotherapy anymore
13:00-13:15	Concluding remarks

A Family of Radiation Oncology Journals from ESTRO

ESTRO and Elsevier proudly announce three new open access journals in the field of radiation oncology to accompany the premier journal in the field, *Radiotherapy & Oncology*. ESTRO's family of journals further the Society's mission to foster the role of radiation oncology to improve the care of patients with cancer.




Clinical and Translational Radiation Oncology – ctRO

All aspects of clinical and translational radiation oncology research, particularly new developments in radiobiology, clinical interventions and treatments, data sciences, epidemiology, and oncology.

Editors-in-Chief:

Pierre Blanchard, *Villejuif, France*

Daniel Zips, *Tübingen, Germany*




Physics and Imaging in Radiation Oncology – phiRO

Medical physics and imaging in radiation oncology.

Editors-in-Chief:

Lorenzo Bonomo, *Rome Italy*

Ludvig Muren, *Aarhus, Denmark*



Technical Innovations and Patient Support in Radiation Oncology – tipsRO

Technology and patient care, including treatment planning, workflows and delivery; treatment verification; supportive care; psycho-oncology; patient reported outcome measures; risk management; radiotherapy quality management and control; and personalisation.

Editors-in-Chief:

Sara Faithfull, *Guildford, UK*

Michelle Leech, *Dublin, Ireland*

Read volume 1 and submit your own work

www.ctro.science • www.phiro.science • www.tipsro.science



SCIENTIFIC PROGRAMME

Conference remarks

Opening remarks

09:00 - 09:15 | Auditorium

09:00 Chair: H. Langendijk (The Netherlands)

09:05 Chair: C.R. Leemans (The Netherlands)

09:10 Chair: J.P. Machiels (Belgium)

Keynote lecture

Immunotherapy for head and neck cancer: integrating the fourth modality

09:15 - 09:45 | Auditorium

Chair: H. Langendijk (The Netherlands)

Chair: C.R. Leemans (The Netherlands)

Chair: J.P. Machiels (Belgium)

09:15 Immunotherapy for head and neck cancer: integrating the fourth modality

Speaker: R. Ferris (USA)

SP-001

Keynote lecture

State of the art in robotic surgery

09:45 - 10:15 | Auditorium

Chair: H. Langendijk (The Netherlands)

Chair: C.R. Leemans (The Netherlands)

Chair: J.P. Machiels (Belgium)

09:45 State of the art in robotic surgery

Speaker: E. Moore (USA)

SP-002

Symposium

Prognostic modelling

10:45 - 12:00 | Auditorium

Chair: R. Brakenhoff (The Netherlands)

Chair: J.P. Klussmann (Germany)

10:45	Radiomics: the poor man molecular imaging? <i>Speaker: P. Lambin (The Netherlands)</i>	SP-003
11:10	Novel insights into head and neck cancer by transcriptome approaches <i>Speaker: L. De Cecco (Italy)</i>	SP-004
11:35	The TRIPOD guideline <i>Speaker: K.G.M. Moons (The Netherlands)</i>	SP-005

Proffered papers

Proffered papers 1

12:00 - 13:00 | Auditorium

Chair: M. Merlano (Italy)

12:00	Outcomes of head and neck cancer with N3 Nodal Disease: A review of the National Cancer Data Base <i>H.C. Ko (USA), S. Chen, A. Wieland, M. Yu, A. Baschnagel, J. Brower, T. McCulloch, G. Hartig, P. Harari, M. Witek</i>	OC-006
12:10	Sentinel node biopsy for early stage oral cancer; experience of 2 Dutch head and neck centers <i>L. Den Toom (The Netherlands), L. Janssen, R. Van Es, O. Hoekstra, H. Karagozoglou, B. De Keizer, A. Van Schie, S. Willems, S. Van Weert, R. Leemans, E. Bloemena, R. De Bree</i>	OC-007
12:20	Incidence of malignant disease outside the head and neck region in head and neck cancer <i>M. Bernsdorf (Denmark), A. Loft, A. Berthelsen, L. Specht, J. Kjems, A. Gothelf, C. Kristensen, J. Friborg</i>	OC-008

12:30 Validation of a prognostic model in 600 patients with squamous cell carcinoma

J.H. Rasmussen (Denmark), H. Katrin, I.R. Vogelius, J. Friberg, B.M. Fischer, L. Specht

OC-009

12:40 Discussant: J. Guigay (France)

Randomised trials

New data from randomised trials

14:30 - 16:00 | Auditorium

Chair: J. Vermorken (Belgium)

14:30 Update of the meta-analysis of chemotherapy in head and neck cancer (MACH-NC)

Speaker: P. Blanchard (USA)

SP-010

14:45 Discussant: L. Licitra (Italy)

14:52 Update of the PET NECK trial

Speaker: H. Mehanna (UK)

SP-011

15:07 Discussant: W. Budach (Germany)

15:14 Update of neck dissection trial

Speaker: A. D'Cruz (India)

SP-012

15:29 Discussant: R. De Bree (The Netherlands)

15:36 Update on the ARCON study

Speaker: J. Kaanders (The Netherlands)

SP-013

15:51 Discussant: S. Nuyts (Belgium)

Symposium

Reductions of radiation induced toxicities

16:30 - 17:45 | Auditorium

Chair: W. Budach (Germany)

Chair: J. Giralt (Spain)

16:30	Target volume reduction <i>Speaker: W. De Neve (Belgium)</i>	SP-014
16:55	Prophylactic swallowing exercises in head and neck radiotherapy <i>Speaker: H.R. Mortensen (Denmark)</i>	SP-015
17:20	The value of proton therapy for head and neck malignancies: reducing side effects and improving outcomes <i>Speaker: P. Blanchard (USA)</i>	SP-016

Keynote lecture

New imaging techniques

09:00 - 09:30 | Auditorium

Chair: L. Licitra (Italy)

Chair: M. Quer (Spain)

09:00 New imaging techniques
Speaker: R. Maroldi (Italy)

SP-017

Keynote lecture

HNC Biomarkers - how do we translate biology into useful assays for clinical care?

09:30 - 10:00 | Auditorium

Chair: L. Licitra (Italy)

Chair: M. Quer (Spain)

09:30 HNC Biomarkers - how do we translate biology into useful assays for clinical care?
Speaker: T. Seiwert (USA)

SP-018

Proffered papers

Proffered papers 2

10:30 - 11:30 | Auditorium

Chair: P. Szturz (Czech Republic)

10:30 The phase III study INTERCEPTOR: preliminary results
N. Denaro (Italy), S. Vecchio, A. Bagicalupo, E. Russi, M. Rampino, M. Benasso, G. Numico, L. Licitra, O. Ostellino, M. D'amico, P. Curcio, M. Merlano

OC-019

10:40 Sarcopenia predicts chemotherapy dose-limiting toxicity in patients with head and neck cancer
S.L. Bril (The Netherlands), A.W. Wendrich, J.E. Swartz, I. Wegner, A. De Graeff, E.J. Smid, R. De Bree, A.J. Pothen

OC-020

10:50	<p>Biomarker results from BERIL-1: buparlisib and paclitaxel in patients with platinum-pretreated SCCHN <i>D. Soulières (Canada), S. Faivre, R. Mesía, E. Remenár, S.H. Li, A. Karpenko, A. Dechaphunkul, U. Keilholz, L. Kiss, J.C. Lin, R. Nagarkar, L. Tamás, S.B. Kim, J. Erfán, A. Alyasova, A. Yovine, S. Le Mouhaër, N. Solovieff, S. Turri, L. Licitra</i></p>	OC-021
11:00	<p>Association of patient derived xenograft formation with oral cavity squamous cell cancer outcomes <i>A. Hope (Canada), C. Karamboulas, W. Xu, S. Huang, J. Kim, S. Bratman, J. Cho, J. Ringash, M. Giuliani, A. Bayley, J. Waldron, B. Perez-Ordonez, D. Goldstein, J. De Almeida, D. Brown, J. Irish, P. Gullane, R. Gilbert, B. O'Sullivan, L. Ailles</i></p>	OC-022
11:10	<p>Discussant: J. Vermorken (Belgium)</p>	

Symposium

New developments in surgery

11:30 - 12:45 | Auditorium

Chair: P. Nicolai (Italy)

Chair: K. Harrington (UK)

11:30	<p>New developments in sentinel node biopsy of head and neck cancer <i>Speaker: S. Stoeckli (Switzerland)</i></p>	SP-023
11:55	<p>Integrated 3D virtual visualisation of pathology and reconstructive planning in head and neck cancer <i>Speaker: M. Witjes (The Netherlands)</i></p>	SP-024
12:20	<p>Oropharyngeal surgery <i>Speaker: T. Jones (UK)</i></p>	SP-025

Interactive tumour board session

Limited T4a larynx cancer

14:15 - 15:15 | Auditorium

Chair: *H.E. Eckel (Austria)*

Panellists: A. Castro (Portugal)
J.G. Eriksen (Denmark)
W. Golusinski (Poland)
A. Argiris (Greece)
S. Tribius (Germany)
D. Chevalier (France)

Poster discussion

Poster discussion

15:15 - 16:00 | Auditorium

Chair: *C. Simon (Switzerland)*

Correlation and prognostic impact of HPV and p16 on RT-outcome in larynx and hypopharynx cancer

P. Lassen (Denmark), M. Schou, J. Overgaard, J. Alsner

PD-026

cfHPV DNA as a marker of treatment results in patients with HPV-related head and neck cancer

T. Rutkowski (Poland), A. Mazurek, M. Snietura, A. Wygoda, M. Kentnowski, P. Polanowski, U. Dworzecka, B. Pilecki, K. Dębiec, I. Gawron, J. Niedzialek, W. Pięłowski, U. Bojko, P. Widlak, K. Skladowski

PD-027

Prognostic and predictive impact of HPV status in oropharyngeal cancer: the MARCH-HPV project

B. Lacas (France), P. Lassen, A. Trotti, B. Zackrisson, Q. Zhang, J.P. Pignon, J. Overgaard, P. Blanchard

PD-028

15:15 Discussant: J. Hess (Germany)

Causes-of-death underestimate the burden of head and neck cancers in France (EPICORL study)

Y. Pointreau (France), L. Sagaon Teyssier, L. Geoffrois, M. Bec,

	<i>C. Godard, C. Even, L. Lévy-Bachelot, F. Huguét, S. Témam, M. Schwarzingler</i>	PD-029
	Survival of patients with head and neck cancers in France (EPICORL study) <i>F. Huguét (France), L. Geoffrois, B. Le Vu, Y. Pointreau, M. Bec, C. Even, L. Lévy-Bachelot, S. Témam, M. Schwarzingler</i>	PD-030
	Quality of life, health status and work in head and neck cancer survivors treated with radiotherapy <i>Á. Matías-Pérez (Spain), B. G. Díaz de Tudanca, G. Gallego-Herreros, M. Sánchez-Barba, P. Soria-Carreras, A. Nieto-Palacios, A. Rodríguez-Gutierrez, L.A. Pérez-Romasanta</i>	PD-031
15:30	Discussant: A. Mäkitie (Finland) Pharyngeal constrictor muscle dose correlated with dysphagia after radiotherapy in head and neck <i>J. Miroir (France), J. Biau, N. Saroul, C. Millardet, M. Lapeyre</i>	PD-032
	Cetuximab + RT shows an excellent long term OS in patients with both high ADCC and high EGFR <i>M. Merlano (Italy), L. Lattanzio, N. Denaro, D. Vivenza, G. Milano, R. Vigna Taglianti, A. Merlotti, M. Ferrero, C. Lo Nigro</i>	PD-033
	Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer <i>E. Orlandi (Italy), G. Infante, R. Granata, N. Iacovelli, R. Miceli, A. Cavallo, S. Alfieri, C. Bergamini, C. Resteghini, D. Galbiati, L. Locati, S. Tana, S. Naimo, C. Fallai, L. Licitra, P. Bossi</i>	PD-034
15:45	Discussant: D. Raben (USA)	

Symposium

New developments in systemic treatment

16:30 - 17:45 | Auditorium

Chair: J.E. Bakema (The Netherlands)

Chair: J. Vermorken (Belgium)

- | | | |
|-------|--|--------|
| 16:30 | Is there still a role for targeted signaling agents in head and neck cancer?
<i>Speaker: C. Le Tourneau (France)</i> | SP-035 |
| 16:55 | Immunity and immune toxicity: clinical management of immune checkpoint inhibition
<i>Speaker: U. Keilholz (Germany)</i> | SP-036 |
| 17:20 | Immunotherapy beyond anti PD1 inhibitors
<i>Speaker: P. Coulie (Belgium)</i> | SP-037 |

SATURDAY 18 MARCH 2017

Keynote lecture

Clinical implementation of adaptive radiotherapy: challenges ahead

08:45 - 09:15 | Auditorium

Chair: V. Budach (Germany)

Chair: A. Mäkitie (Finland)

08:45 Clinical implementation of adaptive radiotherapy: challenges ahead

Speaker: O. Hamming-Vrieze (The Netherlands)

SP-038

Symposium

Adenoid cystic carcinoma

09:15 - 10:30 | Auditorium

Chair: R. De Bree (The Netherlands)

Chair: S. Faivre (France)

09:15 Adenoid cystic carcinoma: considerations in surgical approach and factors modifying expected outcome following treatment

Speaker: V. Vander Poorten (Belgium)

SP-039

09:40 Radiotherapy in adenoid cystic carcinoma (ACC) of the head and neck

Speaker: A. Jensen (Germany)

SP-040

10:05 When to treat and how to treat distant metastases

Speaker: P. Bossi (Italy)

SP-041

Proffered papers

Proffered papers 3

11:00 - 12:00 | Auditorium

Chair: V. Vander Poorten (Belgium)

11:00 Re-irradiation with curative intent of squamous cell carcinomas of the head and neck in Denmark

B.E. Engelmänn (Denmark), M. Andersen, C. Elmann, M. Farhadi, A. Gothelf, C.R. Hansen, K. Nowicka-Matus, J.B.B. Petersen, E. Samsøe, H.M. Sand, B. Smulders, J. Johansen

OC-042

11:10	<p>Re-irradiation in head and neck cancers: A single institution prospective cohort study <u>R. Salunkhe</u> (India), S. Ghosh Laskar, S. Chakraborty, T. Gupta, A. Budrukkar, V. Murthy, J.P. Agarwal</p>	OC-043
11:20	<p>ART DECO (CRUK/10/018): dose escalated vs standard dose IMRT in locally advanced head and neck cancer <u>M. Beasley</u> (UK), C. Nutting, J. Morden, D. Bernstein, V. Cosgrove, S. Fisher, B. Foran, T. Guerrero-Urbano, D. Gujral, K. Harrington, E. Junor, H. Mehanna, A. Miah, N. Palaniappan, S. Ramkumar, P. Sanghera, M. Sen, A. Sibtain, W. Soe, C. West, D. Piercey, S. Witts, M. Emson, E. Hall</p>	OC-044
11:30	<p>Recurrence patterns after 40 Gy to the elective treated neck in head and neck cancer. <u>D. Nevens</u> (Belgium), F. Duprez, J. Daisne, J. Schatteman, W. De Neve, S. Nuyts</p>	OC-045
11:40	<p>Discussant: C. Grau (Denmark)</p>	

Debate

Early stage HPV related oropharyngeal cancer should not be treated with radiotherapy anymore

12:00 - 13:00 | Auditorium

Chair: V. Grégoire (Belgium)

Chair: R. Simo (UK)

12:00	<p>For the motion <i>Speaker: C. Simon</i> (Switzerland)</p>	SP-046
12:15	<p>Against the motion <i>Speaker: V. Budach</i> (Germany)</p>	SP-047
12:30	<p>For the motion <i>Speaker: J. Klozar</i> (Czech Republic)</p>	SP-048
12:38	<p>Against the motion <i>Speaker: J. Giralt</i> (Spain)</p>	SP-049

Conference remarks


Concluding remarks

13:00 - 13:15 | Auditorium

13:00 H. Langendijk (The Netherlands)

13:05 C.R. Leemans (The Netherlands)

13:10 J.P. Machiels (Belgium)



MAKE SENSE CAMPAIGN 2017

Awareness Week:
18th - 22nd September 2017



European Head & Neck Course
BIRMINGHAM-AMSTERDAM-POZNAN

10th Annual EUROHNC

Poznań 15th - 17th November 2017



*Standards, innovations, perspectives
and possibilities
in head and neck oncology*

Course Directors:

- Wojciech Golusiński (Poland)
- Sat Panmar (United Kingdom)
- René Leemans (The Netherlands)
- Paul Pracy (United Kingdom)

- Main topics:**
- Multidisciplinary treatment of head and neck
 - Neck
 - Oral cavity and oropharyngeal tumours
 - Larynx and hypopharynx
 - Salivary gland tumours
 - Recurrent head and neck cancer
 - Reconstructive surgery
 - HPV in head and neck cancer
 - Modern radiotherapy - protons
 - Chemiotherapy - new frontiers
 - Rehabilitation
 - Future perspectives
 - Skin cancer
 - Case discussion

More information on the website: www.eurohnc.com

2nd Congress of IGR&EHNS

International Guild of Robotic & Endoscopic Head and Neck Surgery



Next-Generation Technology and Surgical Innovation
in Robotics and Endoscopic Head and Neck Surgery



Dates: November 30 ~ December 2, 2017

Place: Olympic Musee, Lausanne, Switzerland

Hosted by

Christian Simon, Congress President,
2nd Congress of IGR&EHNS

Organized by IGR&EHNS

Eun Chang Choi, President of IGR&EHNS
Chris Holsinger, Vice President of IGR&EHNS
C. René Leemans, President of European Head and Neck Society (EHNS)
Wojciech Golusiński, Secretary General of EHNS
Yoon Woo Koh, Secretary General of IGR&EHNS

Homepage: <http://www.igerhns.org>

Contact us: E-mail with@thewithin.co.kr



POSTERS

Poster

Multidisciplinary management

The interplay between all-trans-retinoic acid and radiotherapy in inducing cancer stem cell arrest

L.G. Marcu (Romania), D. Marcu

PO-050

A 7-year overview on advanced nasopharynx's cancer: features influencing survival outcomes

A. Nogueira (Portugal), M. Teixeira, L. Khouri, F. Branquinho, P. Jacinto

PO-051

N2 node metastasis in squamous cancers of head and neck: failure patterns and future management

S. Giri (USA), M.R. Kanakamedala, S. Vijayakumar, S. Mangana, E.L. Bhanat, M.P. Giri, M. Chhabria

PO-052

Impact of PTV coverage on local recurrences and overall survival after IMRT for head and neck cancers

L. Piram (France), T. Frederic-Moreau, J. Miroir, N. Saroul, N. Pham-Dang, L. Berger, J. Biau, M. Lapeyre

PO-053

Cisplatin use in UK head and neck cancer management: a clinician survey of current practice

B. Foran (UK), J. Fenwick, B. Byrne, J. Christian

PO-054

Subglottic squamous cell carcinoma in Denmark from 1971-2016 – a report from the DAHANCA-group

L. Hill-Madsen (Denmark), C.A. Kristensen, E. Andersen, J. Johansen, L.J. Andersen, H. Primdahl, J. Overgaard, N.M. Lyhne

PO-055

Tolerance and outcomes of radical hypofractionated radiotherapy for glottic cancer in the elderly

A. Zeniou, S. Ramasamy (UK), L. Murray, M. Sen, K. Cardale, K. Dyker, R. Prestwich

PO-056

Radiation induced skin reaction in head neck malignancies and assessment of quality of life

V. Pareek (India), M. Chandra, R. Bhalavat

PO-057

Nasopharyngeal carcinoma treated with intensity modulated radiotherapy in a non-endemic area.

A. Lozano (Spain), A. Navarro, H. Letelier, S. Vazquez, V. Navarro, J. Nogues, R. Mesia

PO-058

Efficacy and safety of modified-increased FEP regimen and chemoradiation for locally advanced HNSCC

A. Ouhajjou (Morocco), Z. Fadoukhair, H. Faouzi

PO-059

Dose received by the pituitary gland during irradiation of nasopharyngeal carcinoma

N. Sellami (Tunisia), W. Siala, H. Daoud, W. Mnejja, T. Sahnoun, L. Farhat, J. Daoud

PO-060

Stomal underdose in post-laryngectomy radiotherapy via VMAT: phantom study and clinical case analysis

S. Lee (USA), J. Zhang, B.K. Lee, J. Cho-Lim, W.S. Inouye, W.C. Lorentz, M.Y. Leu

PO-061

Retrospective analysis of 72 patients treated with FEP regimen and CCRT for locally advanced NPC

A. Ouhajjou (Morocco), Z. Fadoukhair, H. Faouzi

PO-062

Waiting time and fast track model for head and neck cancer patients in Finland

H. Irjala (Finland), E. Halme, A. Makitie, T. Atula, P. Koivunen

PO-063

Normal tissue complication probability model for tube feeding dependence 6 months after radiotherapy

N. Kanayama (Japan), R.G.J. Kierkels, R.J.H.M. Steenbakkers, A. Van der Schaaf, M. Miyazaki, T. Fujii, K. Nishiyama, J.A. Langendijk, T. Teshima

PO-064

Survival outcomes in unknown primary with nodal metastases and role of radiation therapy

A. Srivastava (India), R. Bhalavat, M. Chandra, V. Pareek

PO-065

Early-stage tonsil cancer submitted to primary surgery and adjuvant therapy: retrospective study

C. Pedro (Portugal), E. Netto, R. Pocinho, A. Mota, P. Pereira, M. Magalhães, P. Montalvão, F. Santos

PO-066

Mucosal Melanoma of the head and neck: single institution experience <i>C. Viveiros (Portugal), E. Netto, A. Mota, R. Pocinho, M. Fortunato, P. Montalvão, M. Magalhães, F. Santos</i>	PO-067
Head and neck cancer of unknown primary origin: a single institution experience <i>N. Ferreira (Portugal), J. Silva, E. Netto, G. Marau, M. Ferreira, F. Santos</i>	PO-068
Radiation dose and distribution following transoral robotic surgery of the palatine tonsil <i>S. Naqvi (USA), J. Ferrell, A. Blanco, J. Bigcas, K. Jain, R. Karni</i>	PO-069
Conventional vs bifractionated radiotherapy in nasopharyngeal cancer 10 years followup of phase 3 trial <i>W. Siala (Tunisia), N. Sellami, N. Toumi, M. Drira, A. Ghorbel, M. Frikha, J. Daoud</i>	PO-070
Dose to the thyroid gland during irradiation of nasopharyngeal carcinoma <i>W. Siala (Tunisia), N. Sellami, H. Daoud, M. Kallel, W. Mnejja, L. Farhat, J. Daoud</i>	PO-071
Compliance and acute toxicity of chemoradiotherapy for undifferentiated nasopharyngeal cancer <i>N. Jovanovic Korda (Serbia), T. Ursulovic, S. Vucicevic, V. Vujanac, M. Kreacic</i>	PO-072
Viable tumour in salvage neck dissections: relation with initial treatment, lymph node size and HPV <i>K. Van den Bovenkamp (The Netherlands), B. Dorgelo, M.G. Noordhuis, B.F.A.M. Van der Laan, B. Van der Vegt, H.P. Bijl, J.L. Roodenburg, B.A.C. Van Dijk, G.B. Halmos, E.M.D. Schuurung, J.A. Langendijk, S.F. Oosting, B.E.C. Plaat</i>	PO-073
Concomitant chemoradiotherapy alone or with induction chemotherapy in advanced head and neck cancer <i>R. Teixeira, A. Cavaleiro, P. Vieira, F. Aveiro, G. Vieira (Portugal)</i>	PO-074
Treatment of nasopharyngeal cancer: a Serbian institutional experience <i>T. Ursulovic (Serbia), N. Babovic</i>	PO-075

Predictive and prognostic value of pretreatment FDG-PET SUV parameters in head and neck

L. Deantonio (Italy), M. Paolini, E. Puta, E. Ferrara, L. Vigna, R. Matheoud, G. Sacchetti, M. Brambilla, M. Krengli

PO-076

Cisplatin or Carboplatin in locally advanced head and neck squamous cell carcinoma

Abstract withdrawn

PO-077

Poster

Innovative treatments

The evaluation of the set-up differences between radiation therapists for head and neck patients

E. Kara (Turkey), A. Yazici, B. Dirican, B. Boybas, M.A. Gunaydin, A. Kartal, M. Akmansu, A. Hicsonmez

PO-078

Hypofractionated versus prolonged chemo-IMRT schedules in oropharyngeal carcinoma

L. Boon (UK), C. Boon, P. Nightingale, J. Cashmore, G. Sangha, M. Hickman, H. Benghiat, C. Fong, P. Sanghera, A. Hartley

PO-079

Challenges and opportunities in head and neck cancer research in the UK: a survey of oncologists

B. Foran (UK), J. Fenwick, B. Byrne, J. Christian

PO-080

Recurrence analysis in head and neck squamous cell carcinoma treated with adjuvant EUD-based IMRT

S. Welz (Germany), T. Schönle, D. Thorwarth, D. Zips

PO-081

Correlation between HI, GI, CI and size of metastases for linac-based high dose SRT / SRS

B. Tas (Turkey), I.F. Durmus, A. Okumus, O.E. Uzel

PO-082

Adaptative radiotherapy for nasopharyngeal carcinoma

L. Farhat (Tunisia), W. Mnejja, T. Sahnoun, F. Dhoubib, J. Daoud

PO-083

HDR interstitial brachytherapy for head and neck malignancies with Iridium 192 implants

V. Pareek (India), R. Bhalavat, M. Chandra

PO-084

<p>Role of L glutamine in reducing severity of chemoradiation induced mucositis and improve QoL in HNC <i>V. Pareek (India), R. Bhalavat, M. Chandra</i></p>	PO-085
<p>Brachial plexus position reproducibility for head and neck radiotherapy and its dosimetric impact <i>S. English (UK), A. Thompson</i></p>	PO-086
<p>Adaptive 18F-FDG-PET-guided reirradiation for recurrent and second primary head and neck cancer <i>J. Schatteman (Belgium), D. Van Gestel, D. Berwouts, W. De Gersem, I. Goethals, L. Olteanu, S. Rottey, T. Vercauteren, W. De Neve, F. Duprez</i></p>	PO-087
<p>The study of constant dose rate and gantry speed arc therapy for glottic carcinoma on Varian 23EX <i>R. Zhang, Y. Gao, W. Bai (China), M. Miao, D. Liu</i></p>	PO-088
<p>Melatonin enhances the toxicity of radio- and chemotherapy in head and neck cancer cells <i>G. Escames (Spain), B.I. Fernández-Gil, A. Guerra-Librero, Y. Shen, S. García-López, J. Florido, R. Sayed, D. Acuña-Castroviejo, J. Esposito</i></p>	PO-089
<p>Oncostatic effect of melatonin in head and neck cancer: role of mitochondrial function <i>G. Escames (Spain), A. Guerra-Librero, Y. Shen, J. Florido, R. Sayed, M. Molina-Navarro, M. Gonzalez-Diez, D. Acuña-Castroviejo, J. Esposito</i></p>	PO-090
<p>Intensity modulated radiotherapy (IMRT) in nasopharyngeal cancer – a dosimetric and QoL analysis <i>V. Pareek (India), R. Bhalavat, M. Chandra</i></p>	PO-091
<p>Dosimetric comparaiso of conformal and intensity modulated radiotherapy for locally recurrent NPC <i>W. Mnejja (Tunisia), L. Farhat, H. Daoud, T. Sahnoun, N. Fourati, W. Siala, J. Daoud</i></p>	PO-092
<p>COSTAR trial results: 3-D Conformal Radiotherapy vs Cochlea-Sparing IMRT in parotid cancer patients <i>C. Nutting, J. Morden, M. Beasley, S. Bhide (UK), M. Emson, M. Evans, L. Fresco, D. Gujral, K. Harrington, C. Lemon, R. Neupane, K. Newbold, R. Prestwich, M. Robinson, P. Sanghera, M. Sivaramalingam, M. Sydenham, E. Wells, S. Witts, E. Hall</i></p>	PO-093

Radiation induced volume changes in salivary glands in head and neck cancer patients receiving IMRT

D. Borade (India), M. Chandra, R. Bhalavat, L. Nellore, K. George, K. Kalariya, V. Pareek, Z. Moosa, N. Reddy, A. Shrivastava

PO-094

Electrochemotherapy for mucosal head and neck tumours: results from a phase II clinical trial.

C.C. Plaschke (Denmark), J. Gehl, H. Johannesen, H. Hendel, K. Kiss, R. Hansen, I. Wessel

PO-095

Dosimetric evaluation of volumetric modulated arc therapy (VMAT) in sinonasal cancer radiotherapy

E. Donini (Italy), S. Magi, S. Ricci, E. Pasquini, G. Frezza

PO-096

Poster

Biology, HPV and molecular targeting

Droplet digital PCR for detection of circulating tumour DNA in blood of head and neck cancer patients

J.H. Van Ginkel (The Netherlands), M.M.H. Huibers, R.J.J. Van Es, R. De Bree, S.M. Willems

PO-097

Searching for therapeutic targets from whole transcriptome of oral cancer

B. Roy (India), N. De Sarkar, R. Singh

PO-098

Human papillomavirus in head and neck cancer in the UK: a clinician survey of current practice

B. Foran (UK), J. Fenwick, B. Byrne, J. Christian

PO-099

Oral cancer microenvironment - PI3K/AKT/mTOR and ERK/MAPK pathways dependent targets

C. Domingues (Portugal), M. Laranjo, A.M. Abrantes, A.B. Sarmento-Ribeiro, L. Carvalho, M.F. Botelho, H. Silva, M. Dourado

PO-100

Osteopontin (OPN) as an instant, predictive marker of tumour hypoxia in head and neck cancer patients

J. Mrochem-Kwarciak (Poland), T. Rutkowski, A. Wygoda, R. Deja, A. Hajduk, Ł. Boguszewicz, P. Widlak, K. Składowski

PO-101

EGFR detection in saliva as an easy diagnostic and prognostic tool in oral squamous cell cancer

C. Piazza (Italy), A. Paderno, L. Zanotti, E. Bandiera, F. Del Bon, C. Romani, P. Perotti, E. Bignotti, N. Montalto, R. Morello, F.E. Odicino, P. Nicolai, A. Ravaggi

PO-102

Oropharyngeal cancer patient-derived xenografts: characterisation and radiosensitivity.

J. Lilja-Fischer (Denmark), B. Ulhøi, J. Alsner, P. Lassen, V. Nielsen, J. Overgaard

PO-103

Everolimus in oral cancer: a potential therapeutic approach dependent on cell type?

C. Domingues (Portugal), P. Matafome, S. Neves, M. Laranjo, R. Seíça, M.F. Botelho, A.B. Sarmento-Ribeiro, M. Dourado

PO-104

Is there justification for age bias in HPV p16 testing for oropharyngeal squamous cell carcinoma?

S. McCauley (UK), P. McCloskey, C. Lyons, K. Brown, K. Rooney, F. Houghton

PO-105

Prognostic significance of cyclin D1 and pRb expression in oropharyngeal carcinoma

M.A. Broglie (Switzerland), M.M. Plath, S.J. Stoeckli, W. Jochum

PO-106

Clinical outcomes of HPV-positive non-oropharyngeal squamous cell carcinoma: analysis of the NCDB

H. Ko (USA), R. Sacotte, M. Yu, S. Chen, A. Wieland, M. Witek

PO-107

TLR induced PDL-1 expression in HNSCC as a potential tool of immunomodulation

B. Wollenberg (Germany), R. Pries, M. Drenckhahn, K. Ploetze-Martin, B. Wollmann

PO-108

Poster

Imaging and radiomics

The added value of SPECT-CT for identification of sentinel lymph nodes in early stage oral cancer

L. Den Toom (The Netherlands), A. Van Schie, S. Van Weert, O. Hoekstra, H. Karagozoglou, E. Bloemena, R. De Bree

PO-109

Analysis of loco-regional failures after IMRT for HNSCC using deformable image registration

R. Zukauskaite (Denmark), C.R. Hansen, J. Johansen, C. Grau, J. Overgaard, C. Brink

PO-110

Dermal backflow: NIRFLI pattern associated multimodality therapy in patients with oropharynx cancer

S. Naqvi (USA), I. Tan, J. Rasmussen, M. Aldrich, J. Morrow, A. Blanco, C. Gutierrez, K. Jain, E. Sevick-Muraca, R. Karni

PO-111

Role for interim PET in patient selection for dose escalation and boost volume definition in HNSCC

J. Lynch (UK), A. Nisbet, C. Clark, S. Whitaker, K. Wood

PO-112

Dynamics of biological imaging parameters in PW-MRI and FMISO-PET/CT during chemoradiation of SCCHN

A. Bunea, H. Bunea (Germany), C. Stoykow, L. Majerus, N. Wiedenmann, M. Mix, P. Meyer, M. Bock, A.L. Grosu

PO-113

Alterations in tumour hypoxia in serial F-MISO/PET-CT during chemoradiation in HNSCC

H. Bunea, A. Bunea (Germany), L. Majerus, C. Stoykow, M. Mix, A.L. Grosu

PO-114

A [18F]FDG-PET adaptive thresholding algorithm delineation of RT tumour volumes of head and neck cancer

L. Deantonio (Italy), M. Paolini, L. Vigna, G. Loi, L. Masini, G. Sacchetti, R. Matheoud, M. Brambilla, M. Krengli

PO-115

Potential applications of spectral CT imaging in patients with head and neck squamous cell carcinoma

B. Peltenburg (The Netherlands), J.W. Dankbaar, M.J. Willemink, R. De Bree, T. Leiner

PO-116

Poster

Supportive care, quality of life, rehabilitation

Swallowing exercises: will it really help head and neck cancer patients? <i>W. Hashem (Egypt), R. Abdelkader, L. Abdelkader, S. Elhadary, K. Mashhour</i>	PO-117
Acute and late toxicities in patients with oral cancer treated with intensity-modulated radiotherapy <i>A. Cristaudo (Italy), S. Ursino, D. Delishaj, F. Matteucci, A. Molinari, F. Païar</i>	PO-118
Does mucosal appearance predict mucosal PRO in oropharyngeal carcinoma treated with chemo IMRT? <i>M. Hickman (UK), T. Shantakuma, S. Meade, C. Fong, P. Sanghera, A. Hartley</i>	PO-119
Head and neck cancers are associated with poor EQ-5D-related utility in France (EPICORL study) <i>M. Schwarzingler (France), F. Huguet, S. Témam, Y. Pointreau, M. Bec, C. Even, L. Geoffrois, L. Lévy-Bachelot, S. Luchini</i>	PO-120
Fentanyl Pectin Nasal Spray in head and neck cancer irradiation. First results of the PecDICO study <i>Y. Pointreau (France), G. Bera, C. Sire, A. Ruffier, G. Janoray, G. Calais, R. Bensadoun, M. Bollet, B. Pinel, L. Martin, X. Amores</i>	PO-121
Psychological profile of patients with head and neck cancer during radiotherapy: preliminary data <i>M. Massaccesi (Italy), L. Dinapoli, A. Pesce, F. Miccichè, R. Autorino, A. Tenore, M. Balducci, V. Valentini</i>	PO-122
Hypothyroidism after radiotherapy of head and neck – incidence and risk factors. <i>U. Dworzecka (Poland), A. Wygoda, T. Rutkowski, B. Pilecki, K. Składowski</i>	PO-123
A melatonin gel protects the mitochondria from radiation damage preventing mucositis <i>G. Escames (Spain), F. Ortiz, B. Fernández-Gil, A. Guerra-Librero, Y. Shen, J. Florido, D. Acuña-Castroviejo</i>	PO-124

Effects of melatonin oral gel to prevent radiation-induced mucositis model in rat

G. Escames (Spain), C. Tarrago, F. Ortiz, B. Fernández-Gil, N. Lluch, A. Guerra-Librero, Y. Shen, J. Florido, D. Acuña-Castroviejo, R. Bosser

PO-125

Consenting patients for late-effects of head and neck radiotherapy: an audit of UK oncology practice

J.A. Christian (UK), J. Fenwick, B. Foran

PO-126

Melatonin oral gel for prevention oral mucositis head and neck cancer undergoing chemo/bio radiation (MUCOMEL)

A. Lozano (Spain), J. Marruecos, N. Farre, J. Giralt, R. Morera, I. Planas, M. Lanzuela, A. Escribano, L.A. Glaria, R. Mesia, J. Rubio, A. Lopez-Pousa, N. Baste, B. Castelo, B. Cirauqui, J. Martinez-Trufero, J. Ortiz, P.M. Grima, V. Valenti, C. Tarrago, R. Bosser

PO-127

Follow up dysphagia in head and neck cancers is related to RT dose received by swallowing structures

K. George (India), R. Bhalavat, M. Chandra, L. Nellore, D. Borade, K. Kalariya, V. Pareek, Z. Moosa, N. Reddy, A. Srivastava

PO-128

Managing the consequences of head and neck in radiotherapy a Radiotherapy late effects clinic

J. Christian (UK), E. Stones, E. Hallam

PO-129

Longitudinal assessment of enteral nutrition requirement in 1st line treatment of SCCHN

M.N. Falewee (France), C. Michel, C. Hebert, E. Chamorey

PO-130

Poster

Minimal invasive and reconstructive surgery

Resecting the carotid artery for invasive head and neck cancer: time to reconsider its feasibility

A. Jones (UK), C. Daultry, J.C. Wilton

PO-131

Risk of re-operation for bleeding in head and neck surgery

E. Haapio (Finland), I. Kinnunen, J. Airaksinen, H. Irjala, T. Kiviniemi

PO-132

Occult lymphnode metastasis in early stage OPC treated with TORS without neck lymphnodes dissection

D. Alterio (Italy), G. Marvaso, S.F. Zorzi, L. Preda, A. Ferrari, A. Rappa, G. Giugliano, F. Maffini, D. Sibio, C. Francia, M. Cossu Rocca, B.A. Jereczek-Fossa, M. Ansarin

PO-133

Retrospective analysis of treatment outcomes of sinonasal malignancies. Our 22-year experience

P. Tarchini (Italy), P. Farneti, A. Bellusci, V. Sciarretta, E. Donini, G. Frezza, A. Tosoni, A. Brandes, E. Pasquini

PO-134

Poster

Epidemiology and prevention

Head and neck squamous cell carcinoma of unknown primary treated in the era of FDG-PET and IMRT

M. De Ridder (The Netherlands), W.M.C. Klop, O. Hamming-Vrieze, J.P. De Boer, W. Vogel, M.W.M. Van den Brekel, A. Al-Mamgani

PO-135

Hospital costs associated with head and neck cancer by phase-of-care in France (EPICORL study)

M. Schwarzwinger (France), F. Huguet, L. Sagaon Teyssier, S. Téمام, Y. Pointreau, M. Bec, C. Even, L. Lévy-Bachelot, L. Geoffrois

PO-136

Multivariate oral rinse models predict head and neck squamous cell carcinoma (HNSCC)

M. Donovan (USA), I. Reis, K. Curtis, F. Khan, E. Franzmann

PO-137

Poster

Salivary gland, skull base, skin and thyroid cancers

IMRT of sino-nasal cancer: improved results compared to 3D radiotherapy

T. Frédéric-Moreau (France), L. Piram, J. Miroir, N. Saroul, C. Millardet, F. Kiakowski, M. Lapeyre, J. Biau

PO-138

Hypofractionated accelerated chemo-Tomotherapy for nasopharyngeal cancer: 2-year treatment outcomes

C.T.K. Fong (UK), C.S. Boon, P. Sanghera, A. Hartley

PO-139

Long-term outcomes of surgery ± radiotherapy for salivary gland carcinoma at a single institution

J. Williams (Australia)

PO-140

Adenoid cystic carcinoma of the head and neck: solid growth pattern as an adverse prognostic factor

J. Fonseca (Portugal), C. Viveiros, E. Netto, S. Esteves, I. Fonseca, P. Montalvão, M. Magalhães, F. Santos

PO-141

A 10-year review of primary major salivary glands carcinomas

H. Magalhães (Portugal), F. Pereira, C. Vieira, A. Isabel, M. Jácome, J. Dinis

PO-142

Salivary gland tumours: preliminary results of the Trento Protontherapy Centre

I. Giacomelli (Italy), D. Scartoni, M. Cianchetti, F. Dionisi, S. Lemoine, M. Amichetti

PO-143

Poster

Special requirements for elderly patients

Chronic radiation-associated dysphagia after curative reirradiation. Does age affect?

L. Gutierrez Bayard (Spain), M. Salas Buzón, E. Porras Alonso, S. Garduño Sánchez, M. Macías, L. De Ingunza Barón, E. González Calvo, I. Villanego Beltrán, L. Díaz Gómez, V. Díaz Díaz

PO-144

Definitive sequential radiotherapy in elderly patients with locally advanced oropharyngeal cancer

F. De Felice (Italy), A. Galdieri, G. Abate, N. Bulzonetti, D. Musio, V. Tombolini

PO-145

Radiotherapy in elderly patients aged ≥ 70 years with head and neck squamous cell carcinoma

E. Metcalfe (Turkey), D. Etiz, A. Ozen

PO-146

The ELAN program: Customized treatment of SCCHN elderly patients according to geriatric assessment

J. Guigay (France), C. Ortholan, H. Le Caer, S. Renard-oldrini, X. Sun, L. Mayache-badis, L. Geoffrois, J. Fayette, C. Even, D. Vansteene, Y. Pointreau, D. Schwob, N. Vintonenko, C. Michel, J. Bourhis, A. Auperin, C. Mertens

PO-147

Hypofractionated radiotherapy for head and neck cancer patients unfit for standard treatment

I. Desideri (Italy), P. Bonomo, C. Ciabatti, C. Muntoni, M. Lo Russo, M. Loi, D. Greto, I. Meattini, L. Livi

PO-148

Survival outcomes for very elderly patients after definitive radiotherapy for head and neck cancer

L.M. Dixon (UK), K. Garcez, L.W. Lee, A.J. Sykes, N.J. Slevin, D.J. Thomson

PO-149

Age ≥ 70 is not an adverse prognostic factor for accelerated radiotherapy in head and neck cancer

C. Terhaard (The Netherlands), N. Kasperts, H. Dehnad, E. Smid, L. Janssen, R.G. Wiggendaad, C.P.J. Raaijmakers

PO-150

Poster

Immunodiagnosis and immunotherapy

Immunotherapy for refractory brain metastasis in cases of oropharyngeal squamous cell carcinoma


M. Bhandari (USA), P. Vora, A. Dugar, S. Bhati, A. DeFranco, E. Guenther

PO-151

An abstract network diagram consisting of interconnected nodes and lines, rendered in shades of white and light blue, located in the bottom left corner of the page.

EXHIBITION

FLOORPLAN



ESTRO - European Society for Radiotherapy and Oncology	10
EHNS - European Head and Neck Society	20
ESMO - European Society for Medical Oncology	30
WISEPRESS MEDICAL BOOKSHOP	40
MERCK KGAA	50
BRISTOL-MYERS SQUIBB	100
AZANTA DANMARK A/S	160
NORGINE	170
VARIAN MEDICAL SYSTEMS INTERNATIONAL AG	180
MSD	200

COMPANY DETAILS

AZANTA DANMARK A/S

160

Gearhalsvej 1
2500 Valby
Denmark

☎ +45 70 25 95 45

☎ +45 70 25 95 46

✉ info@azanta.com

🖱 www.azanta.com

BRISTOL-MYERS SQUIBB

100

34 D. Princeton Pike
Lawrence Township – NJ 08648
USA

🖱 www.bms.com

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis. The Bristol-Myers Squibb Foundation's philanthropic programs seek to promote health equity and improve the health outcomes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world's most vulnerable people.

EUROPEAN HEAD AND NECK SOCIETY (EHNS)

20

Secretary EHNS
Department of Head and Neck Surgery
Garbary 15, 61 – 866 Poznań
Poland

✉ secretary@ehns.org

🖱 www.ehns.org

The European Head and Neck Society (EHNS): A True Multidisciplinary Platform for Head and Neck Oncology.

The EHNS was founded in 2006 and it is the final result of a road towards a true European multidisciplinary platform

on head and neck tumours. The First European Conference on Head and Neck Cancer took place in the French city of Lille in November 2001. The subsequent conferences were held bi-annually in Lille, Zagreb, Athens, Poznań, Liverpool and Budapest. The number of participants grew each time, indicating an immense interest in the interdisciplinary approach to head and neck cancer. The intent of the EHNS is to promote exchange of knowledge in all aspects of head and neck neoplastic diseases and to promote the highest standards of research, education and training, disease prevention and patient care. It is a multi-disciplinary body bringing together clinicians and other health professionals, basic scientists and patient organisations involved in any aspect of Head and Neck Oncology. Presently, 19 European countries are members of the EHNS.

EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO)

30

Via Luigi Taddei, 4
6962 Viganello - Lugano
Switzerland

☎ +41 (0)91 973 19 00

☎ +41 (0)91 973 19 02

✉ esmo@esmo.org

🖱 www.esmo.org

ESMO is the leading professional organisation for medical oncology. With more than 15,000 members representing oncology professionals from over 130 countries, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.

ESMO's educational resources support an integrated, multi-professional approach to cancer care. We have European roots and a global reach: we welcome oncology professionals from around the world and we seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide.

EUROPEAN SOCIETY FOR RADIO-THERAPY AND ONCOLOGY (ESTRO) 10

Rue Martin V, 40
1200 Brussels
Belgium
☎ +32 2 775 93 40
☎ +32 2 779 54 94
✉ info@estro.org
👉 www.estro.org

Founded in 1980, the European Society for Radiotherapy and Oncology, ESTRO, is a non-profit and scientific organization that advances all aspects of radiation oncology in order to improve patients' care in the multimodality treatment of cancer.

With over 6,700 members in and outside Europe, ESTRO supports all the radiation oncology professionals in their daily practice: radiation oncologists, medical physicists, radiobiologists, RTT (radiation therapists) and the wider oncology community.

In order to achieve this, the Society promotes education, science dissemination and access to radiotherapy through its teaching courses, conferences, publications and public affairs activities.

MERCK KGAA 50

Frankfurter Str 250
64293 Darmstadt
Germany

☎ +49 6151 72 -0
☎ +49 6151 72 91 3652
✉ service@merckgroup.com
👉 www.merckgroup.com

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, alongside helping patients with infertility, endocrine and metabolic disorders as well as cardiovascular diseases, to cutting-edge systems for scientific research and production, and furthermore liquid crystals for smartphones and LCD televisions. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

MSD 200

600 Corporate Dr.
Lebanon, NJ 08833
USA
👤 David Suggitt
☎ +1 908 236 4492
☎ +1 908 236 4735
✉ david.suggitt@merck.com
👉 www.merck.com

For 125 years, MSD has been a global health care leader working to help the world be well.

NORGINE B.V. 170

Hogehilweg 7
1101 CA Amsterdam
The Netherlands
👤 Enrico Seccamani
☎ +31 20 567 0900
☎ +31 20 567 0999
✉ eseccamani@norgine.com
👉 www.norgine.com

VARIAN MEDICAL SYSTEMS INTERNATIONAL AG 180

Hinterbergstrasse 14
CH-6330 Cham
Switzerland
👤 Nicole Leitch
☎ +41 41 749 88 44
✉ nicole.leitch@varian.com
👉 www.varian.com

WISEPRESS MEDICAL BOOKSHOP 40

15 Lyon Road
Merton
London, SW19 2RL
UK
✉ marketing@wisepress.com
👉 www.wisepress.com

ACKNOWLEDGEMENT TO THE INDUSTRY

Many thanks to the following companies for their support to this meeting:

BRISTOL-MYERS SQUIBB
MERCK KGAA
MSD

and to all companies having supported the participation of some delegates in the conference and / or participating in the technical exhibition.

MADRID
2017

ESMO

congress

esmocongress.org

ESMO 2017

CALL FOR ABSTRACTS

MADRID SPAIN
8-12 SEPTEMBER 2017

Integrating science into oncology
for a better patient outcome

Organiser

ESMO

GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

Partner

EACR

European Association
for Cancer Research

IMPORTANT DEADLINES

10 May 2017 Abstract submission

7 June 2017 Early registration

19 July 2017 Late-breaking abstracts

9 August 2017 Late registration



SATELLITE SYMPOSIA

BRISTOL-MYERS SQUIBB

Thursday 16 March 2017

13:15 – 14:15

Auditorium

(Lunch boxes provided)

Emerging trends in immuno-oncology research for squamous cell carcinoma of the head and neck

Chair: Ethan Argiris, MD, PhD Greece/USA

- 13:15-13:20 Welcome and introductions
Ethan Argiris, MD, PhD, Greece/USA
- 13:20-13:35 Establishing I-O in SCCHN
Ethan Argiris, MD, PhD, Greece/USA
- 13:35-13:55 Evolution of SCCHN research: the study of I-O combinations as potential treatment options
Robert Ferris, MD, PhD, USA
- 13:55-14:10 Patient-reported outcomes and clinical considerations for I-O in SCCHN
Lisa Licitra, MD, Italy
- 14:10-14:15 Close and audience Q&A
Ethan Argiris, MD, PhD, USA

Visit Bristol-Myers Squibb at booth # 100 for more information.

THURSDAY 16 MARCH 2017

MERCK SHARP & DOHME (MSD)

Thursday 16 March 2017

17:55-18:55

Auditorium

The promise of the immunologic approach to HNSCC

Scientific symposium sponsored by MSD

Chair & Moderator: Ezra Cohen

17:55-18:00 Introduction and welcome

E. Cohen, Professor of Medicine, University of California, San Diego, Moores Cancer Center (USA)

18:00-18:20 Understanding the rationale behind immunologic treatment approach for HNSCC

E. Cohen

18:20-18:40 Data updates from immunotherapeutic agents in HNSCC

T. Seiwert, Associate Program Director (Head and Neck Cancer), The University of Chicago, University of Chicago Medical Center (USA)

18:40-18:55 Q&A

Faculty

Visit MSD at booth # 200 for more information.

MERCK KGAA

Friday March 17, 2017

13:00 – 14:00

Auditorium

(Lunch boxes provided)

Patient voices: answering with evidence and experience

Chairs: Ezra Cohen (USA), Ricard Mesía (Spain)

Faculty: Jean Bourhis (Switzerland), Anthony Chan (Hong Kong), Lisa Licitra (Italy)

- 13:00-13:05 Patient voices in SCCHN
Ricard Mesía
- 13:05-13:25 Patient expectations for LA SCCHN treatment: what are our current answers and what does the future hold?
- 13:05-13:15 Recommended treatment options in LA SCCHN: what do my patients want to know?
Anthony Chan
- 13:15-13:25 Alternative treatment options in LA SCCHN: what are my patients asking?
Jean Bourhis
- 13:25-13:35 Panel discussion
Ezra Cohen
- 13:35–13:45 The need for response in R/M SCCHN: what are my patients looking for?
Lisa Licitra
- 13:45–13:55 Panel discussion
Ricard Mesía
- 13:55–14:00 Patient voices: we are listening
Ezra Cohen

Visit Merck KGaA at booth # 50 for more information.



AUTHORS INDEX

Abate, G.	PO-145	Bignotti, E.....	PO-102
Abdelkader, L.....	PO-117	Bijl, H.	SP-013
Abdelkader, R.	PO-117	Bijl, H.P.	PO-073
Abrantes, A.M.	PO-100	Blanchard, P.	SP-010, SP-016, PD-028
Acuña-Castroviejo, D.	PO-089, PO-090, PO-124, PO-125	Blanco, A.	PO-069, PO-111
Agarwal, J.P.	OC-043	Bloemena, E.	OC-007, PO-109
Ailles, L.	OC-022	Bock, M.	PO-113
Airaksinen, J.	PO-132	Boguszewicz, Ł.	PO-101
Akmansu, M.	PO-078	Bojko, U.	PD-027
Aldrich, M.	PO-111	Bollet, M.	PO-121
Al-Mamgani, A.	PO-135	Bonomo, P.	PO-148
Alfieri, S.	PD-034	Boon, C.	PO-079
Alsner, J.	PD-026, PO-103	Boon, C.S.	PO-139
Alterio, D.	PO-133	Boon, I.	PO-079
Alyasova, A.	OC-021	Borade, D.	PO-094, PO-128
Amichetti, M.	PO-143	Bosser, R.	PO-125, PO-127
Amores, X.	PO-121	Bossi, P.	PD-034
Andersen, E.	PO-055	Botelho, M.F.	PO-100, PO-104
Andersen, L.J.	PO-055	Bots, W.	SP-013
Andersen, M.	OC-042	Bourhis, J.	SP-010, PO-147
Ansarin, M.	PO-133	Boybas, B.	PO-078
Atula, T.	PO-063	Brambilla, M.	PO-076, PO-115
Auperin, A.	PO-147	Brandes, A.	PO-134
Autorio, R.	PO-122	Branquinho, F.	PO-051
Aveiro, F.	PO-074	Bratman, S.	OC-022
Babovic, N.	PO-075	Bril, S.I.	OC-020
Bagicalupo, A.	OC-019	Brink, C.	PO-110
Bai, W.	PO-088	Brogie, M.A.	PO-106
Balducci, M.	PO-122	Brower, J.	OC-006
Bandiera, E.	PO-102	Brown, D.	OC-022
Baschnagel, A.	OC-006	Brown, K.	PO-105
Baste, N.	PO-127	Budrukkar, A.	OC-043
Bayley, A.	OC-022	Bulzonetti, N.	PO-145
Beasley, M.	OC-044, PO-093	Bunea, A.	PO-114, PO-113
Bec, M.	PD-029, PD-030, PO-120, PO-136	Bunea, H.	PO-113, PO-114
Bellusci, A.	PO-134	Byrne, B.	PO-054, PO-080, PO-099
Benasso, M.	OC-019	Calais, G.	PO-121
Benghiat, H.	PO-079	Cardale, K.	PO-056
Bensadoun, R.	PO-121	Carvalho, L.	PO-100
Bera, G.	PO-121	Cashmore, J.	PO-079
Bergamini, C.	PD-034	Castelo, B.	PO-127
BERGER, L.	PO-053	Cavaleiro, A.	PO-074
Bernsdorf, M.	OC-008	Cavallo, A.	PD-034
Bernstein, D.	OC-044	Chakraborty, S.	OC-043
Berthelsen, A.	OC-008	Chamorey, E.	PO-130
Berwouts, D.	PO-087	Chandra, M.	PO-057, PO-065, PO-084, PO-085, PO-091, PO-094, PO-128
Bhalavat, R.	PO-057, PO-065, PO-084, PO-085, PO-091, PO-094, PO-128	Chen, S.	OC-006, PO-107
Bhanat, E.L.	PO-052	Chhabria, M.	PO-052
Bhandari, M.	PO-151	Cho-Lim, J.	PO-061
Bhati, S.	PO-151	Cho, J.	OC-022
Bhide, S.	PO-093	Christian, J.	PO-129, PO-054, PO-080, PO-099
Biau, J.	PD-032, PO-138, PO-053	Christian, J.A.	PO-126
Bigcas, J.	PO-069	Ciabatti, C.	PO-148

Cianchetti, M.....	PO-143	Dorgelo, B.....	PO-073
Cirauqui, B.....	PO-127	Dourado, M.....	PO-100, PO-104
Clark, C.....	PO-112	Drenckhahn, M.....	PO-108
Cosgrove, V.....	OC-044	drira, M.....	PO-070
Cossu Rocca, M.....	PO-133	Dugar, A.....	PO-151
Coulie, P.....	SP-037	Duprez, F.....	OC-045, PO-087
Cristaudo, A.....	PO-118	Durmus, I.F.....	PO-082
Curcio, P.....	OC-019	Dworzecka, U.....	PO-123, PD-027
Curtis, K.....	PO-137	Dyker, K.....	PO-056
D'amico, M.....	OC-019	Elhadary, S.....	PO-117
D'Cruz, A.....	SP-012	Elmann, C.....	OC-042
Daisne, J.....	OC-045	Emson, M.....	OC-044, PO-093
Dankbaar, J.W.....	PO-116	Engelmann, B.E.....	OC-042
Daoud, H.....	PO-060, PO-071, PO-092	English, S.....	PO-086
Daoud, J.....	PO-060, PO-070, PO-071, PO-092, PO-083	Erfán, J.....	OC-021
Daultry, C.....	PO-131	Escames, G.....	PO-089, PO-090, PO-124, PO-125
De Almeida, J.....	OC-022	Escribano, A.....	PO-127
de Boer, J.P.....	PO-135	Esposito, J.....	PO-089
de Bree, R.....	OC-007, OC-020, PO-097, PO109, PO-116	Esteves, S.....	PO-141
De Cecco, L.....	SP-004	Etiz, D.....	PO-146
De Felice, F.....	PO-145	Evans, M.....	PO-093
De Gerssem, W.....	PO-087	Even, C.....	PD-029, PD-030, PO-120, PO-136, PO-147
de Graeff, A.....	OC-020	Exposito, J.....	PO-090
de Ingunza Barón, L.....	PO-144	fadoukhaïr, Z.....	PO-059, PO-062
de Jong, M.....	SP-013	Faivre, S.....	OC-021
de Keizer, B.....	OC-007	Falewee, M.N.....	PO-130
De Neve, W.....	SP-014, OC-045, PO-087	Fallai, C.....	PD-034
de Ridder, M.....	PO-135	faouzi, H.....	PO-059, PO-062
De Sarkar, N.....	PO-098	Farhadi, M.....	OC-042
Deantonio, L.....	PO-076, PO-115	Farhat, L.....	PO-060, PO-071, PO-083, PO-092
Dębiec, K.....	PD-027	Farneti, P.....	PO-134
Dechaphunkul, A.....	OC-021	Farre, N.....	PO-127
DeFranco, A.....	PO-151	Fayette, J.....	PO-147
Dehnad, H.....	PO-150	Fenwick, J.....	PO-054, PO-080, PO-099, PO-126
Deja, R.....	PO-101	Fernández-Gil, B.....	PO-124, PO-125
Del Bon, F.....	PO-102	Fernández-Gil, B.L.....	PO-089
Delaere, P.....	SP-039	Ferrara, E.....	PO-076
Delishaj, D.....	PO-118	Ferrari, A.....	PO-133
den Toom, I.....	OC-007, PO-109	Ferreira, M.....	PO-068
Denaro, N.....	OC-019, PD-033	Ferreira, N.....	PO-068
Desideri, I.....	PO-148	Ferrell, J.....	PO-069
Dhouib, F.....	PO-083	Ferrero, M.....	PD-033
Díaz Díaz, V.....	PO-144	Ferris, R.....	SP-001
Díaz Gómez, L.....	PO-144	Fischer, B.M.....	OC-009
Dinapoli, L.....	PO-122	Fisher, S.....	OC-044
Dimis, J.....	PO-142	Florido, J.....	PO-089, PO-090, PO-124, PO-125
Dionisi, F.....	PO-143	Fong, C.....	PO-079, PO-119
Dirican, B.....	PO-078	Fong, C.T.K.....	PO-139
Dixon, L.M.....	PO-149	Fonseca, I.....	PO-141
Domingues, C.....	PO-100, PO-104	Fonseca, J.....	PO-141
Donini, E.....	PO-096, PO-134	Foran, B.....	PO-054, PO-080, PO-099, OC-044, PO-126
Donovan, M.....	PO-137		
Doornaert, P.....	SP-013		

Fortunato, M.....	PO-067	Hall, E.	OC-044, PO-093
Fourati, N.	PO-092	Hallam, E.....	PO-129
Francia, C.	PO-133	Halme, E.....	PO-063
Frank, S.J.....	SP-016	Halmos, G.B.....	PO-073
Franzmann, E.	PO-137	Hamming-Vrieze, O.....	SP-038, PO-135
Frédéric-Moreau, T.....	PO-053, PO-138	Hansen, C.R.....	OC-042, PO-110
Fresco, L.....	PO-093	Hansen, R.....	PO-095
Frezza, G.....	PO-096, PO-134	Harari, P.....	OC-006
Friberg, J.....	OC-008, OC-009	Harrington, K.....	OC-044, PO-093
frikha, M.....	PO-070	Hartig, G.....	OC-006
Fujii, T.	PO-064	Hartley, A.....	PO-079, PO-119,
G. Díaz de Tudanca, B.....	PD-031		PO-139
Galbiati, D.....	PD-034	Hashem, W.....	PO-117
Galdieri, A.....	PO-145	HEBERT, C.....	PO-130
Gallego-Herreros, G.....	PD-031	Hendel, H.....	PO-095
Gao, Y.....	PO-088	Hickman, M.....	PO-119, PO-079
Garcez, K.....	PO-149	Hicsonmez, A.....	PO-078
García-López, S.....	PO-089	Hill-Madsen, L.....	PO-055
Guarduño Sánchez, S.....	PO-144	Hoekstra, O.....	OC-007, PO-109
Gawron, I.....	PD-027	Hope, A.....	OC-022
Gehl, J.....	PO-095	Houghton, F.....	PO-105
Geoffrois, L.....	PD-029, PD-030,	Huang, S.....	OC-022
	PO-120, PO-136,	Huguet, F.....	PD-030, PD-029,
	PO-147		PO-120, PO-136
George, K.....	PO-094, PO-128	Huibers, M.M.H.....	PO-097
Ghorbel, A.....	PO-070	Iacovelli, N.....	PD-034
Ghosh Laskar, S.....	OC-043	Infante, G.....	PD-034
Giacomelli, I.....	PO-143	Inouye, W.S.....	PO-061
Gilbert, R.....	OC-022	Irish, J.....	OC-022
Giralt, J.....	SP-049, PO-127	Irjala, H.....	PO-063, PO-132
Giri, M.P.....	PO-052	Isabel, A.....	PO-142
Giri, S.....	PO-052	Jacinto, P.....	PO-051
Giugliano, G.....	PO-133	Jácome, M.....	PO-142
Giuliani, M.....	OC-022	Jain, K.....	PO-069, PO-111
Glaria, L.A.....	PO-127	Janoray, G.....	PO-121
Godard, C.....	PD-029	Janssen, L.....	OC-007, PO-150
Goethals, I.....	PO-087	Janssens, G.....	SP-013
Goldstein, D.....	OC-022	Jensen, A.....	SP-040
González Calvo, E.....	PO-144	Jerezek-Fossa, B.A.....	PO-133
Gonzalez-Diez, M.....	PO-090	Jochum, W.....	PO-106
Gothelf, A.....	OC-008, OC-042	Johannesen, H.....	PO-095
Granata, R.....	PD-034	Johansen, J.....	OC-042, PO-055,
Grau, C.....	PO-110		PO-110
Greto, D.....	PO-148	John C. Rasmussen, J.....	PO-111
Grima, P.M.....	PO-127	Jones, A.....	PO-131
Grosu, A.L.....	PO-113, PO-114	Jones, T.....	SP-025
Guenther, E.....	PO-151	Jovanovic Korda, N.....	PO-072
Guerra-Librero, A.....	PO-089, PO-090,	Junor, E.....	OC-044
	PO-124, PO-125	Kaanders, J.....	SP-013
Guerrero-Urbano, T.....	OC-044	Kalariya, K.....	PO-094, PO-128
Guigay, J.....	PO-147	kallel, M.....	PO-071
Gujral, D.....	OC-044, PO-093	Kanakamedala, M.R.....	PO-052
Gullane, P.....	OC-022	Kanayama, N.....	PO-064
Gunaydin, M.A.....	PO-078	Kara, E.....	PO-078
Gupta, T.....	OC-043	Karagozlu, H.....	OC-007, PO-109
Gutierrez, C.....	PO-111	Karamboulas, C.....	OC-022
Gutierrez Bayard, L.....	PO-144	Karni, R.....	PO-069, PO-111
Haapio, E.....	PO-132	Karpenko, A.....	OC-021
Hajduk, A.....	PO-101	Kartal, A.....	PO-078

Kasperts, N.....	PO-150	Lo Russo, M.....	PO-148
Katrin, H.....	OC-009	Locati, L.....	PD-034
Keilholz, U.....	SP-036, OC-021	Loft, A.....	OC-008
Kentnowski, M.....	PD-027	Loi, G.....	PO-115
Khan, F.....	PO-137	Loi, M.....	PO-148
Khouri, L.....	PO-051	Lopez-Pousa, A.....	PO-127
Kiakowski, F.....	PO-138	Lorentz, W.C.....	PO-061
Kierkels, R.G.J.....	PO-064	Lozano, A.....	PO-058, PO-127
Kim, J.....	OC-022	Luchini, S.....	PO-120
Kim, S.B.....	OC-021	Lyhne, N.M.....	PO-055
Kinnunen, I.....	PO-132	Lynch, J.....	PO-112
Kiss, K.....	PO-095	Lyons, C.....	PO-105
Kiss, L.....	OC-021	Macias, M.....	PO-144
Kiviniemi, T.....	PO-132	Maffini, F.....	PO-133
Kjems, J.....	OC-008	Magalhães, H.....	PO-142
Klop, W.M.C.....	PO-135	Magalhães, M.....	PO-066, PO-067, PO-141
Klozar, J.....	SP-048	Magi, S.....	PO-096
Ko, H.....	PO-107	Majerus, L.....	PO-113, PO-114
Ko, H.C.....	OC-006	Makitie, A.....	PO-063
Koivunen, P.....	PO-063	Mangana, S.....	PO-052
Kreacic, M.....	PO-072	Marau, G.....	PO-068
Krengli, M.....	PO-076, PO-115	Marcu, D.....	PO-050
Kristensen, C.....	OC-008	Marcu, L.G.....	PO-050
Kristensen, C.A.....	PO-055	Marruecos, J.....	PO-127
Kunal S. Jain, K.....	PO-069, PO-111	Martin, L.....	PO-121
Lacas, B.....	PD-028, SP-010	Martinez-Trufero, J.....	PO-127
Landais, C.....	SP-010	Marvaso, G.....	PO-133
Langendijk, J.A.....	PO-064, PO-073	Mashhour, K.....	PO-117
Lanzuela, M.....	PO-127	Masini, L.....	PO-115
LAPEYRE, M.....	PD-032, PO-138, PO-053	Massaccesi, M.....	PO-122
Laranjo, M.....	PO-100, PO-104	Matafome, P.....	PO-104
Lassen, P.....	PD-026, PD-028, PO-103	Matheoud, R.....	PO-076, PO-115
Lattanzio, L.....	PD-033	Matías-Pérez, A.....	PD-031
Le Caer, H.....	PO-147	Matteucci, F.....	PO-118
Le Mouhaër, S.....	OC-021	Mayache-Badis, L.....	PO-147
Le Tourneau, C.....	SP-035	Mazurek, A.....	PD-027
Le Vu, B.....	PD-030	McCauley, S.....	PO-105
Lee, B.K.....	PO-061	McCloskey, P.....	PO-105
Lee, L.W.....	PO-149	McCulloch, T.....	OC-006
Lee, S.....	PO-061	Meade, S.....	PO-119
Leemans, R.....	OC-007	Meattini, I.....	PO-148
Leiner, T.....	PO-116	Mehanna, H.....	SP-011, OC-044
Lemoine, S.....	PO-143	Merlano, M.....	PD-033, OC-019
Lemon, C.....	PO-093	Merlotti, A.....	PD-033
Letelier, H.....	PO-058	Mertens, C.....	PO-147
Leu, M.Y.....	PO-061	Mesia, R.....	PO-058, PO-127, OC-021
Lévy-Bachelot, L.....	PD-029, PD-030, PO-120, PO-136	Metcalfe, E.....	PO-146
Lì, S.H.....	OC-021	Meulemans, J.....	SP-039
Licitra, L.....	OC-019, OC-021, PD-034	Meyer, P.....	PO-113
Lilja-Fischer, J.....	PO-103	Miah, A.....	OC-044
Lin, J.C.....	OC-021	Miao, M.....	PO-088
Liu, D.....	PO-088	Miccichè, F.....	PO-122
Livi, L.....	PO-148	Miceli, R.....	PD-034
Lluch, N.....	PO-125	Michel, C.....	PO-130, PO-147
Lo Nigro, C.....	PD-033	Milano, G.....	PD-033
		Millardet, C.....	PD-032, PO-138
		Miroir, J.....	PD-032, PO-138,

	PO-053	Ouhajjou, A.....	PO-059, PO-062
Mix, M.	PO-113, PO-114	Overgaard, J.	PD-026, PD-028,
Miyazaki, M.	PO-064		PO-055, PO-103,
Mnejja, W.	PO-060, PO-071,		PO-110
	PO-092, PO-083	Ozen, A.....	PO-146
Molina-Navarro, M.	PO-090	Paderno, A.	PO-102
Molinari, A.	PO-118	Paier, F.	PO-118
Montalto, N.	PO-102	Palaniappan, N.	OC-044
Montalvão, P.	PO-066, PO-067,	Paolini, M.	PO-076, PO-115
	PO-141	Pareek, V.	PO-057, PO-084,
Moosa, Z.	PO-094, PO-128		PO-085, PO-091,
Morden, J.	OC-044, PO-093		PO-065, PO-094,
Morello, R.	PO-102		PO-128
Morera, R.	PO-127	Pasquini, E.	PO-096, PO-134
Morrow, J.	PO-111	Pedro, C.	PO-066
Mortensen, H.R.	SP-015	Peltenburg, B.	PO-116
Mota, A.	PO-066, PO-067	Pereira, F.	PO-142
Mrochem-Kwarciak, J.	PO-101	Pereira, P.	PO-066
Muntoni, C.	PO-148	Perez-Ordóñez, B.	OC-022
Murray, L.	PO-056	Pérez-Romasanta, L.A.	PD-031
Murthy, V.	OC-043	Perotti, P.	PO-102
Musio, D.	PO-145	Pesce, A.	PO-122
Nagarkar, R.	OC-021	Petersen, J.B.B.	OC-044
Naimo, S.	PD-034	Petit, C.	SP-010
Naqvi, S.	PO-069, PO-111	Pham-Dang, N.	PO-053
Navarro, A.	PO-058	Piazza, C.	PO-102
Navarro, V.	PO-058	Piercey, D.	OC-044
Nellore, L.	PO-094, PO-128	Pigłowski, W.	PD-027
Netto, E.	PO-066, PO-067,	Pignon, J.P.	PD-028, SP-010
	PO-068, PO-141	Pilecki, B.	PD-027, PO-123
Neupane, R.	PO-093	Pinel, B.	PO-121
Nevens, D.	OC-045	Piram, L.	PO-138, PO-053
Neves, S.	PO-104	Plaat, B.E.C.	PO-073
Newbold, K.	PO-093	Planas, I.	PO-127
Nicolai, P.	PO-102	Plaschke, C.C.	PO-095
Niedzialek, J.	PD-027	Plath, M.M.	PO-106
Nielsen, V.	PO-103	Ploetze-Martin, K.	PO-108
Nieto-Palacios, A.	PD-031	Pocinho, R.	PO-066, PO-067
Nightingale, P.	PO-079	Pointreau, Y.	PD-029, PO-121,
Nisbet, A.	PO-112		PD-030, PO-120,
Nishiyama, K.	PO-064		PO-136, PO-147
Nogueira, A.	PO-051	Polanowski, P.	PD-027
Nogues, J.	PO-058	Porrás Alonso, E.	PO-144
Noordhuis, M.G.	PO-073	Pothen, A.J.	OC-020
Nowicka-Matus, K.	OC-042	Preda, L.	PO-133
Numico, G.	OC-019	Prestwich, R.	PO-056, PO-093
Nutting, C.	OC-044, PO-093,	Pries, R.	PO-108
	SP-047	Primdahl, H.	PO-055
Nuyts, S.	OC-045	Putz, E.	PO-076
O'Sullivan, B.	OC-022	Raaijmakers, C.P.J.	PO-150
Odicino, F.E.	PO-102	Ramasamy, S.	PO-056
Okumus, A.	PO-082	Ramkumar, S.	OC-044
Olteanu, L.	PO-087	Rampino, M.	OC-019
Oosting, S.F.	PO-073	Rappa, A.	PO-133
Orlandi, E.	PD-034	Rasmussen, J.H.	OC-009
Ortholan, C.	PO-147	Rasmussen, J.	PO-111
Ortiz, F.	PO-124, PO-125	Ravaggi, A.	PO-102
Ortiz, J.	PO-127	Reddy, N.	PO-094, PO-128
Ostellino, O.	OC-019	Reis, I.	PO-137

Remenár, E.....	OC-021	Silva, H.....	PO-100
Renard-Oldrini, S.	PO-147	Silva, J.....	PO-068
Resteghini, C.....	PD-034	Simon, C.....	SP-046
Ricci, S.	PO-096	Singh, R.	PO-098
Ringash, J.....	OC-022	Sire, C.....	PO-121
Robinson, M.	PO-093	Sivaramalingam, M.....	PO-093
Rodríguez-Gutierrez, A.	PD-031	Skladowski, K.	PD-027, PO-101, PO-123
Romani, C.	PO-102	Slevin, N.J.....	PO-149
Roodenburg, J.L.	PO-073	Smid, E.....	PO-150
Rooney, K.	PO-105	Smid, E.J.	OC-020
Rottey, S.	PO-087	Smulders, B.	OC-042
Roy, B.	PO-098	Snietura, M.....	PD-027
Rubio, J.....	PO-127	Soe, W.	OC-044
Ruffier, A.	PO-121	Solovieff, N.....	OC-021
Russi, E.....	OC-019	Soria-Carreras, P.	PD-031
Rutkowski, T.	PD-027, PO-101, PO-123	Soulières, D.	OC-021
Sacchetti, G.	PO-076, PO-115	Span, P.	SP-013
Sacotte, R.	PO-107	Specht, L.	OC-008, OC-009
Sagaon Teyssier, L.	PD-029, PO-136	Srivastava, A.....	PO-065, PO-128
Sahnoun, T.	PO-060, PO-083, PO-092	Steenbakkers, R.J.H.M.	PO-064
Salas Buzón, M.	PO-144	Stoeckli, S.	SP-023
Salunkhe, R.	OC-043	Stoeckli, S.J.	PO-106
Samsøe, E.	OC-042	Stones, E.	PO-129
Sánchez-Barba, M.....	PD-031	Stoykov, C.	PO-113, PO-114
Sand, H.M.	OC-042	Sun, X.....	PO-147
Sangha, G.	PO-079	Swartz, J.E.....	OC-020
Sanghera, P.....	OC-044, PO-079, PO-093, PO-119, PO-139	Sydenham, M.....	PO-093
Santos, F.....	PO-066, PO-067, PO-068, PO-141	Sykes, A.J.	PO-149
Sarmento-Ribeiro, A.B.....	PO-100, PO-104	Tamás, L.....	OC-021
Saroul, N.....	PD-032, PO-138, PO-053	Tan, I.	PO-111
Sayed, R.	PO-089, PO-090	Tana, S.	PD-034
Scartoni, D.....	PO-143	Tarchini, P.....	PO-134
Schatteman, J.	PO-087, OC-045	Tarrago, C.....	PO-125, PO-127
Schönle, T.	PO-081	Tas, B.....	PO-082
Schou, M.	PD-026	Teixeira, M.	PO-051
Schuuring, E.M.D.	PO-073	Teixeira, R.	PO-074
Schwarzinger, M.....	PO-120, PO-136, PD-029, PD-030	Témam, S.....	PD-030, PD-029, PO-120, PO-136
Schwob, D.....	PO-147	Tenore, A.	PO-122
Sciarretta, V.	PO-134	Terhaard, C.	PO-150, SP-013
Seiça, R.....	PO-104	Teshima, T.....	PO-064
Sellami, N.	PO-070, PO-071, PO-060	Thompson, A.	PO-086
Sen, M.....	OC-044, PO-056	Thomson, D.J.....	PO-149
Sevick-Muraca, E.	PO-111	Thorwarth, D.....	PO-081
Shantakuma, T.....	PO-119	Tombolini, V.	PO-145
Shen, Y.	PO-089, PO-090, PO-124, PO-125	Tosoni, A.	PO-134
Shrivastava, A.	PO-094	toumi, N.	PO-070
Siala, W.	PO-060, PO-070, PO-071, PO-092	Trotti, A.	PD-028
Sibio, D.....	PO-133	Turri, S.	OC-021
Sibtain, A.	OC-044	Ulhøi, B.	PO-103
		Ursino, S.	PO-118
		Ursulovic, T.	PO-075, PO-072
		Uzel, O.E.....	PO-082
		Valenti, V.	PO-127
		Valentini, V.....	PO-122
		van den Bovenkamp, K.....	PO-073
		van den Brekel, M.W.M.	PO-135
		van den Ende, P.	SP-013

van der Laan, B.F.A.M.....	PO-073	Yu, M.....	OC-006, PO-107
van der Schaaf, A.	PO-064	Zackrisson, B.	PD-028
van der Vegt, B.....	PO-073	Zanotti, L.....	PO-102
van Dijk, B.A.C.....	PO-073	Zeniou, A.....	PO-056
van Es, R.....	OC-007	Zhang, J.....	PO-061
van Es, R.J.J.	PO-097	Zhang, Q.....	PD-028
Van Gestel, D.....	PO-087	Zhang, R.....	PO-088
van Ginkel, J.H.	PO-097	Zips, D.....	PO-081
van Schie, A.	OC-007, PO-109	Zorzi, S.F.....	PO-133
van Weert, S.....	OC-007, PO-109	Zukauskaite, R.....	PO-110
Vander Poorten, V.....	SP-039		
Vansteene, D.....	PO-147		
Vazquez, S.	PO-058		
Vecchio, S.	OC-019		
Vercauteren, T.....	PO-087		
Vergeer, M.....	SP-013		
Vieira, C.....	PO-142		
Vieira, G.	PO-074		
Vieira, P.....	PO-074		
Vigna Taglianti, R.	PD-033		
Vigna, L.	PO-076, PO-115		
Vijayakumar, S.....	PO-052		
Villanego Beltrán, I.....	PO-144		
Vintonenko, N.....	PO-147		
Viveiros, C.....	PO-067, PO-141		
Vivenza, D.....	PD-033		
Vogel, W.....	PO-135		
Vogelius, I.R.	OC-009		
Vora, P.....	PO-151		
Vucicevic, S.	PO-072		
Vujanac, V.....	PO-072		
Waldron, J.....	OC-022		
Wegner, I.	OC-020		
Wells, E.	PO-093		
Welz, S.....	PO-081		
Wendrich, A.W.....	OC-020		
Wessel, I.....	PO-095		
West, C.....	OC-044		
Whitaker, S.....	PO-112		
Widlak, P.....	PD-027, PO-101		
Wiedenmann, N.....	PO-113		
Wieland, A.	OC-006, PO-107		
Wiggenraad, R.G.....	PO-150		
Willemink, M.J.....	PO-116		
Willems, S.....	OC-007		
Willems, S.M.	PO-097		
Williams, J.....	PO-140		
Wilton, J.C.....	PO-131		
Witek, M.....	OC-006, PO-107		
Witjes, M.	SP-024		
Witts, S.....	OC-044, PO-093		
Wollenberg, B.	PO-108		
Wollmann, B.....	PO-108		
Wood, K.....	PO-112		
Wygoda, A.....	PD-027, PO-101, PO-123		
Xu, W.....	OC-022		
Yazici, A.	PO-078		
Yovine, A.	OC-021		



DOVE

DYNAMIC ONCOLOGY
VIRTUAL ESTRO

DOVE

The ESTRO platform for scientific and educational data

DOVE is the e-library developed by ESTRO giving you access to educational and scientific material, produced and disseminated by the Society: the *Green Journal* articles, conference abstracts, webcasts, e-posters, slides, access to FALCON (our delineation tool), guidelines, our newsletter, etc.

How does it work?

DOVE works as a search engine encompassing all kinds of data in radiation oncology. Just type in your key words and then refine your search by ticking the boxes if you are looking for a particular type of support (abstract, webcast, etc.). Or simply type a key word to see all the information available linked to the topic.

How to access DOVE?

Simply go to www.estro.org: DOVE appears on the welcome page. The level of free access to the content you searched will depend on your membership type.

www.estro.org





Combined Drug-Radiation Treatment: Biological Basis, Current Applications and Perspectives

15-18 June 2017 | Brussels, Belgium

Early fee registration deadline on 20 March 2017

From chemo-radiotherapy to immunotherapy and radiation, this course will increase your understanding of combined drug radiation therapy. By the end of the course, you will be able to choose the best combination for each patient and to improve your skills in management of the majority of cancers.

Target Group

The course is aimed at radiation oncologists and medical oncologists involved in the multidisciplinary treatment of cancer.

Course aim

This course aims to:

- Update participants about biological effects of combining drugs and radiation in normal and tumour tissue
- Present evidence-based clinical applications of combined modality treatment using drugs and radiation in major human malignancies
- Stimulate case-based discussion on the interdisciplinary treatment of cancer
- Present future perspectives for combining drugs and radiation.

Register on www.estro.org/school

ESTRO School of Radiotherapy and Oncology



2017

ESTRO
School

POSTGRADUATE COURSES IN EUROPE

Comprehensive and Practical Brachytherapy

5-8 March 2017 | Budapest, Hungary

Particle Therapy

6-10 March 2017 | Essen, Germany

Lower GI: Technical and Clinical Challenges for Radiation Oncologists

22-24 March 2017 | Rome, Italy

Upper GI: Technical and Clinical Challenges for Radiation Oncologists

25-28 March 2017 | Rome, Italy

Dose Modelling and Verification for External Beam Radiotherapy

2-6 April 2017 | Warsaw, Poland

IMRT and Other Conformal Tech- niques in Practice

9-13 April 2017 | Madrid, Spain

ESTRO/ESMIT Course on Molecular Imaging and Radiation Oncology

10-13 April 2017 | Bordeaux, France

Cancer Survivorship

21-23 May 2017 | Brussels, Belgium

Multidisciplinary Management of Prostate Cancer

21-25 May 2017 | Porto, Portugal

Physics for Modern Radiotherapy

4-8 June 2017 | Bucharest, Romania

Advanced Skills in Modern Radiotherapy

11-15 June 2017 | Prague, Czech Republic

Evidence Based Radiation Oncology

11-16 June 2017 | Ljubljana, Slovenia

Combined Drug-Radiation Treat- ment: Biological Basis, Current Applications and Perspectives

15-18 June 2017 | Brussels, Belgium

Target Volume determination - From Imaging to Margins

25-28 June 2017 | Lisbon, Portugal

Brachytherapy for Prostate Cancer

29 June - 1 July 2017 | Brussels, Belgium

Advanced Treatment Planning

3-7 September 2017 | Barcelona, Spain

Clinical Practice and Implementa- tion of Image-Guided Stereotactic Body Radiotherapy

3-7 September 2017 | Budapest, Hungary

Palliative Care and Radiotherapy

7-9 September 2017 | Brussels, Belgium

Multidisciplinary Management of Breast Cancer

10-13 September 2017 | Dublin, Ireland

Research Masterclass in Radiotherapy Physics

10-13 September 2017 | Florence, Italy

Basic Clinical Radiobiology

16-20 September 2017 | Paris, France

Comprehensive Quality Management in Radiotherapy

2-5 October 2017 | Brussels, Belgium

Quantitative Methods in Radiation Oncology: Models, Trials and Clinical Outcomes

8-11 October 2017 | Maastricht,
The Netherlands

Best Practice in Radiation Oncology - Train the RTT Trainers

16-18 October 2017 | Vienna, Austria

Multidisciplinary Management of Brain Tumours

22-24 October 2017 | Vienna, Austria

Image-Guided Radiotherapy and Chemotherapy in Gynaecological Cancer: Focus on MRI Based Adap- tive Brachytherapy

22-26 October 2017 | Prague, Czech Republic

Image Guided Radiotherapy in Clinical Practice

29 October - 2 November 2017 | Athens,
Greece

ESTRO/ESOR Multidisciplinary Approach of Cancer Imaging

2-3 November 2017 | Rome, Italy

Imaging for Physicists

5-9 November 2017 | Malaga, Spain

Paediatric Radiotherapy

30 November - 2 December 2017 | Brussels,
Belgium

POSTGRADUATE COURSES OUTSIDE EUROPE

Transition from Conventional 2D to 3D Radiotherapy with a special emphasis on Brachytherapy in Cervical Cancers

8-11 March 2017 | Bengaluru, India

ESTRO-KOSRO GI: Technical and Clinical Challenges for Radiation Oncologists

2-4 June 2017 | Seoul, South Korea

Comprehensive Quality Management in Radiotherapy

5-9 July 2017 | Chengdu, China

Multidisciplinary Management of Head and Neck Oncology

10-13 December 2017 |
Singapore, Republic of Singapore

PRE-MEETING COURSES

Five Pre-Meeting Courses at ESTRO 36

5 May 2017 | Vienna, Austria

UNDERGRADUATE COURSES

Medical Science Summer School Oncology for Medical Students (Vienna/Groningen)

10-21 July 2017 | Vienna, Austria

ESO-ESSO-ESTRO Multidisciplinary Course in Oncology for Medical Students

28 August - 8 September 2017 | Antwerp, Belgium

- ◆ MULTIMODAL CANCER TREATMENT
- ◆ RADIO THERAPY TREATMENT PLANNING AND DELIVERY
- ◆ BIOLOGY
- ◆ IMAGING
- ◆ RESEARCH
- ◆ BEST PRACTICE

THE 2017 ESTRO CALENDAR
IS SPONSORED BY:

VARIAN
medical systems

Bristol-Myers Squibb.
Research that leads the way in Immuno-Oncology.



Meet us
at the
BMS booth
N° 100

**What if you could help the body's own
immune system combat cancer?
Bristol-Myers Squibb is researching ways
to make this possible.**

At Bristol-Myers Squibb, we're committed to Immuno-Oncology (I-O), a rapidly evolving field that enlists the immune system in the fight against cancer. As we learn more about how cancer evades the immune system, the growing potential of Immuno-Oncology continues to drive our research efforts.



Bristol-Myers Squibb



Immuno-Oncology

LEADING THE WAY.